Oncimmune Holdings PLC (AIM:ONC) has signed a commercial follow-on contract with an unnamed “world-leading” medical research group based in the US.
It will work to validate the findings from a previous study to assess the autoimmune responses to coronavirus infection in immune-compromised patients.
Specifically, new samples will be analysed using Oncimmune’s SeroTag COVID-19 autoantigen array, to confirm the autoimmune reactions already seen in patients with underlying autoimmune diseases, such as irritable bowel disease.
“We have now successfully completed four studies for this world-leading medical research organisation relating to COVID-19,” said chief executive, Dr Adam Hill.
“This latest additional contract, utilising Oncimmune’s validated infectious diseases panel, will proceed to validate the findings from our prior contract.
“This follow-on contract and others we have announced underline Oncimmune’s leading position in autoimmune profiling of infectious disease.”